Therapeutic Drug Monitoring of Antidepressants

Despite evidence to support its potential benefit in clinical practice, therapeutic drug monitoring (TDM) is under-utilised and underdeveloped in the field of psychiatry. In antidepressant pharmacotherapy drug dose is emphasised as the critical treatment variable. However, dose in, and of, itself can be a strikingly misleading predictor of drug concentration and, hence, treatment effect. For antidepressant drugs, plasma concentrations at a given dose have been shown to vary in excess of 40-fold. The clinical relevance of this variability is that at a standard antidepressant dosage only some patients will have tissue drug concentrations associated with an optimal response whereas others will have either low, ineffective drug concentrations or unnecessarily high concentrations which may be poorly tolerated.Among clinicians and healthcare agencies there is an under-appreciation of the degree of pharmacokinetic variability found in patients and how that might impact on the patients response to pharmacotherapy. Hence there is a perception that TDM is an unnecessary, complicated and costly procedure. This is actually unfounded. There are data to suggest that TDM can favourably affect the outcome of antidepressant treatment by providing a rational alternative to the inherently slower, trial and error practice of dosage titration based on clinical response.It is unlikely that TDM will become a standard of care for all antidepressant agents and all patients. Therefore the question becomes for which antidepressant agents, for which patients and under what circumstances, is TDM more cost-effective than traditional dose titration. The use of TDM to optimise the efficient use of selected antidepressant agents could potentially free up healthcare resources to fund other equally deserving treatments. This article provides a discussion of the major classes of antidepressant drugs with regard to their pharmacological features that predict the utility of TDM in clinical practice. Recommendations are made for the practical application of TDM and the directions for further research.

[1]  M. Hamilton A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.

[2]  S. Preskorn,et al.  Antidepressant Response and Plasma Concentrations of Fluoxetine , 1991 .

[3]  S. Preskorn Bupropion: What Mechanism of Action? , 2000 .

[4]  A. T. Harvey,et al.  Biochemical and clinical dose‐response curves with sertraline , 1996 .

[5]  S. Preskorn Antidepressant drug selection: criteria and options. , 1994, The Journal of clinical psychiatry.

[6]  T. Cooper,et al.  Determination of bupropion and its major basic metabolites in plasma by liquid chromatography with dual-wavelength ultraviolet detection. , 1984, Journal of pharmaceutical sciences.

[7]  K. Brøsen,et al.  Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? , 2000, Therapeutic drug monitoring.

[8]  S. Preskorn,et al.  Pharmacoeconomic considerations when evaluating treatment options for major depressive disorder. , 1994, The Journal of clinical psychiatry.

[9]  J. Mendels,et al.  Sertraline safety and efficacy in major depression: A double-blind fixed-dose comparison with placebo , 1995, Biological Psychiatry.

[10]  J. Amsterdam,et al.  Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study. , 1997, The American journal of psychiatry.

[11]  J. Cohn,et al.  Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder. , 1985, The Journal of clinical psychiatry.

[12]  K. Overø Kinetics of citalopram in man; plasma levels in patients , 1982, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[13]  E. A. Allen,et al.  The pharmacokinetics of paroxetine in the elderly , 1989, Acta psychiatrica Scandinavica. Supplementum.

[14]  S. Preskorn,et al.  Clinically Relevant Pharmacology of Selective Serotonin Reuptake Inhibitors , 1997, Clinical Pharmacokinetics.

[15]  M. Dahl,et al.  Pharmacogenetic methods as a complement to therapeutic monitoring of antidepressants and neuroleptics. , 2000, Therapeutic drug monitoring.

[16]  G. Tucker Advances in understanding drug metabolism and its contribution to variability in patient response. , 2000, Therapeutic drug monitoring.

[17]  W. Katon,et al.  The Role of the Primary Care Physician in Patients' Adherence to Antidepressant Therapy , 1995, Medical care.

[18]  P. Renshaw,et al.  Brain kinetics of paroxetine and fluoxetine on the third day of placebo substitution: a fluorine MRS study. , 2000, The American journal of psychiatry.

[19]  J. Wålinder,et al.  Paroxetine: pharmacokinetic and antidepressant effect in the elderly , 1989, Acta psychiatrica Scandinavica. Supplementum.

[20]  P Ley,et al.  Satisfaction, compliance and communication. , 1982, The British journal of clinical psychology.

[21]  P. Janicak Principles and Practice of Psychopharmacotherapy , 1993 .

[22]  C. Beasley,et al.  Fluoxetine versus trazodone: efficacy and activating-sedating effects. , 1991, The Journal of clinical psychiatry.

[23]  S. Preskorn Should bupropion dosage be adjusted based upon therapeutic drug monitoring? , 1991, Psychopharmacology bulletin.

[24]  R. Zerbe,et al.  Fixed-dose fluoxetine therapy for depression. , 1987, Psychopharmacology bulletin.

[25]  J. Wernicke,et al.  Low-dose fluoxetine therapy for depression. , 1988, Psychopharmacology bulletin.

[26]  P. Haffmans,et al.  Venlafaxine serum levels and CYP2D6 genotype. , 2000, Therapeutic drug monitoring.

[27]  A. Coppen,et al.  Drug plasma levels and platelet 5-HT uptake inhibition during long-term treatment with fluvoxamine or lithium in patients with affective disorders. , 1983, British journal of clinical pharmacology.

[28]  L Lemberger,et al.  Fluoxetine: clinical pharmacology and physiologic disposition. , 1985, The Journal of clinical psychiatry.

[29]  C. Bye,et al.  Paroxetine plasma levels: lack of correlation with efficacy or adverse events , 1989, Acta psychiatrica Scandinavica. Supplementum.

[30]  T. Someya,et al.  Steady-state plasma levels of nortriptyline and its hydroxylated metabolites in Japanese patients: impact of CYP2D6 genotype on the hydroxylation of nortriptyline. , 2000, Journal of clinical psychopharmacology.

[31]  J. Davidson,et al.  Seizures and bupropion: a review. , 1989, The Journal of clinical psychiatry.

[32]  L. Tremaine,et al.  Pharmacokinetics of Sertraline and its N-Demethyl Metabolite in Elderly and Young Male and Female Volunteers , 1997, Clinical pharmacokinetics.

[33]  P. Goodnick Blood levels and acute response to bupropion. , 1992, The American journal of psychiatry.

[34]  P. Goodnick Pharmacokinetics of second generation antidepressants: fluoxetine. , 1991, Psychopharmacology bulletin.

[35]  Altamura Ac,et al.  The evidence for 20mg a day of fluoxetine as the optimal dose in the treatment of depression. , 1988 .

[36]  S. Preskorn,et al.  Therapeutic drug monitoring. Principles and practice. , 1993, The Psychiatric clinics of North America.

[37]  J. Cummings,et al.  The neuroanatomy of depression. , 1993, The Journal of clinical psychiatry.

[38]  S. Preskorn Selection of an antidepressant: mirtazapine. , 1997, The Journal of clinical psychiatry.

[39]  S. Preskorn,et al.  Tricyclic antidepressant-induced seizures and plasma drug concentration. , 1992, The Journal of clinical psychiatry.

[40]  S. Preskorn,et al.  Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. , 1994, Journal of clinical psychopharmacology.

[41]  M. Reis,et al.  Therapeutic drug monitoring of sertraline: variability factors as displayed in a clinical setting. , 2000, Therapeutic drug monitoring.

[42]  T. Cooper,et al.  Human brain fluoxetine concentrations. , 1993, The Journal of neuropsychiatry and clinical neurosciences.

[43]  J. Amsterdam,et al.  What constitutes an adequate antidepressant trial for fluoxetine? , 1990, The Journal of clinical psychiatry.

[44]  K. Brøsen,et al.  Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: Nonlinearity and relation to the sparteine oxidation polymorphism , 1992, Clinical pharmacology and therapeutics.

[45]  D. Greenblatt,et al.  Kinetic-dynamic modeling in clinical psychopharmacology. , 1993, Journal of clinical psychopharmacology.

[46]  C. Reist,et al.  Rapid determination of venlafaxine and O-desmethylvenlafaxine in human plasma by high-performance liquid chromatography with fluorimetric detection. , 1997, Journal of chromatography. B, Biomedical sciences and applications.

[47]  E. Richelson,et al.  Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. , 1993, Life sciences.

[48]  D. Kupfer,et al.  The role of neuropharmacologic selectivity in antidepressant action: fluvoxamine versus desipramine. , 1990, The Journal of clinical psychiatry.

[49]  Young Rc,et al.  Desipramine: cardiovascular effects and plasma levels. , 1980 .

[50]  P. Tyrer,et al.  Changes in human whole blood 5-hydroxytryptamine (5-HT) and platelet 5-HT uptake during treatment with paroxetine, a selective 5-HT uptake inhibitor , 1987, Journal of psychopharmacology.

[51]  S. Preskorn,et al.  Somatic therapy for major depressive disorder: selection of an antidepressant. , 1992, The Journal of clinical psychiatry.

[52]  Preskorn Sh Introduction. Pharmacokinetics of psychotropic agents: why and how they are relevant to treatment. , 1993 .

[53]  D. Klein,et al.  Chronological milestones to guide drug change. When should clinicians switch antidepressants? , 1996, Archives of general psychiatry.

[54]  M. Fava,et al.  Accumulation of fluoxetine and norfluoxetine in human brain during therapeutic administration. , 1992, The American journal of psychiatry.

[55]  J. Cain Poor response to fluoxetine: underlying depression, serotonergic overstimulation, or a "therapeutic window"? , 1992, The Journal of clinical psychiatry.

[56]  G. Klerman,et al.  Trends in the prescription of antidepressants by office-based psychiatrists. , 1993, The American journal of psychiatry.

[57]  S. Preskorn,et al.  Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost effectiveness. , 1991, The Journal of clinical psychiatry.

[58]  J. Fabricius,et al.  Paroxetine: pharmacokinetics, tolerance and depletion of blood 5-HT in man. , 2009, Acta pharmacologica et toxicologica.

[59]  M. Garvey,et al.  Serum Fluoxetine and Norfluoxetine Concentrations and Antidepressant Response , 1989, Therapeutic drug monitoring.

[60]  J. Potvin,et al.  Effect of dose escalation after low-dose fluoxetine therapy. , 1989, Psychopharmacology bulletin.

[61]  Karen J. Klamerus,et al.  Introduction of a Composite Parameter to the Pharmacokinetics of Venlafaxine and its Active O‐Desmethyl Metabolite , 1992, Journal of clinical pharmacology.

[62]  M. Kraml,et al.  A High‐Performance Liquid Chromatographic Method for the Simultaneous Determination of Venlafaxine and O‐Desmethylvenlafaxine in Biological Fluids , 1994, Therapeutic drug monitoring.

[63]  L. Balant,et al.  High blood concentrations of imipramine or clomipramine and therapeutic failure: a case report study using drug monitoring data. , 1989, Therapeutic drug monitoring.

[64]  B. Pfohl,et al.  The Relationship Between Antidepressant Response and Tricyclic Antidepressant Plasma Concentrations , 1987, Clinical pharmacokinetics.

[65]  W. Potter,et al.  Bupropion in depression. II. The role of metabolites in clinical outcome. , 1988, Archives of general psychiatry.

[66]  B. Pollock,et al.  Bupropion plasma levels and CYP2D6 phenotype. , 1996, Therapeutic drug monitoring.

[67]  S. Preskorn,et al.  Bupropion Plasma Levels Intraindividual and Interindividual Variability , 1989 .

[68]  R. Barbhaiya,et al.  Clinical Pharmacokinetics of Nefazodone , 1997, Clinical pharmacokinetics.

[69]  Osama Mawlawi,et al.  Differential Occupancy of Somatodendritic and Postsynaptic 5HT1A Receptors by Pindolol: A Dose-Occupancy Study with [11C]WAY 100635 and Positron Emission Tomography in Humans , 2001, Neuropsychopharmacology.

[70]  E. Richelson Pharmacology of antidepressants--characteristics of the ideal drug. , 1994, Mayo Clinic proceedings.

[71]  S. Preskorn,et al.  Plasma levels of imipramine and adverse effects in children. , 1983, The American journal of psychiatry.

[72]  R. Gerner,et al.  The dexamethasone suppression test and response to somatic treatment: a review. , 1986, The Journal of clinical psychiatry.

[73]  T. Cooper,et al.  Effect of plasma from patients containing bupropion and its metabolites on the uptake of norepinephrine , 1986, Neuropharmacology.

[74]  C. Eap,et al.  Marked increase of venlafaxine enantiomer concentrations as a consequence of metabolic interactions: a case report. , 2000, Pharmacopsychiatry.

[75]  K. Brøsen Drug-metabolizing enzymes and therapeutic drug monitoring in psychiatry. , 1996, Therapeutic drug monitoring.

[76]  S. Preskorn,et al.  Central Nervous System Toxicity of Tricyclic Antidepressants: Phenomenology, Course, Risk Factors, and Role of Therapeutic Drug Monitoring , 1990, Journal of clinical psychopharmacology.

[77]  P. Goodnick Pharmacokinetics of second generation antidepressants: bupropion. , 1991, Psychopharmacology bulletin.

[78]  D. H. Schroeder,et al.  Therapeutic drug monitoring of bupropion. , 1990, The American journal of psychiatry.

[79]  J. Haskins,et al.  DMI, Wy-45,030, Wy-45,881 and ciramadol inhibit locus coeruleus neuronal activity. , 1985, European journal of pharmacology.

[80]  R. Veith,et al.  Electrocardiogram changes and plasma desipramine levels during treatment of depression , 1980, Clinical pharmacology and therapeutics.

[81]  S. Preskorn Antidepressants: Neurochemical, Behavioral, and Clinical Perspectives , 1983 .

[82]  G. Dunbar,et al.  Optimal dose regimen for paroxetine. , 1992, The Journal of clinical psychiatry.

[83]  M. Jerling Dosing of antidepressants--the unknown art. , 1995, Journal of clinical psychopharmacology.

[84]  G. Dunbar,et al.  A pharmacokinetic dose titration study in adult and elderly depressed patients , 1989, Acta psychiatrica Scandinavica. Supplementum.

[85]  M. Reis,et al.  Serum Concentrations of Fluoxetine in the Clinical Treatment Setting , 2001, Therapeutic drug monitoring.

[86]  P. Goodnick Pharmacokinetic Optimisation of Therapy with Newer Antidepressants , 1994, Clinical pharmacokinetics.

[87]  Recent developments in the pharmacotherapy of mood disorders. , 1996 .

[88]  A. Rush,et al.  Are fluoxetine plasma levels related to outcome in obsessive-compulsive disorder? , 1996, The American journal of psychiatry.

[89]  S. Preskorn,et al.  Evidence of the dual mechanisms of action of venlafaxine. , 2000, Archives of general psychiatry.

[90]  J. Azuma,et al.  The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population , 2000, European Journal of Clinical Pharmacology.

[91]  B. Rochat,et al.  Analysis of Enantiomers of Citalopram and Its Demethylated Metabolites in Plasma of Depressive Patients Using Chiral Reverse‐Phase Liquid Chromatography , 1995, Therapeutic drug monitoring.

[92]  P. Kragh‐Sørensen,et al.  The kinetics of citalopram: single and multiple dose studies in man. , 2009, Acta pharmacologica et toxicologica.